Zobrazeno 1 - 10
of 282
pro vyhledávání: '"Amy J Johnson"'
Autor:
Bonnie K Harrington, Heather L Gardner, Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Kevin R Coombes, Todd Covey, Allard Kaptein, Michael Gulrajani, Bart Van Lith, Cecile Krejsa, Christopher C Coss, Duncan S Russell, Xiaoli Zhang, Bridget K Urie, Cheryl A London, John C Byrd, Amy J Johnson, William C Kisseberth
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159607 (2016)
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring cani
Externí odkaz:
https://doaj.org/article/885fb92964b3445a99b5a10f0adb8206
Autor:
Erin Hertlein, Kyle A Beckwith, Gerard Lozanski, Timothy L Chen, William H Towns, Amy J Johnson, Amy Lehman, Amy S Ruppert, Brad Bolon, Leslie Andritsos, Arletta Lozanski, Laura Rassenti, Weiqiang Zhao, Tiina M Jarvinen, Leigha Senter, Carlo M Croce, David E Symer, Albert de la Chapelle, Nyla A Heerema, John C Byrd
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76607 (2013)
Studies of chronic lymphocytic leukemia (CLL) have yielded substantial progress, however a lack of immortalized cell lines representative of the primary disease has hampered a full understanding of disease pathogenesis and development of new treatmen
Externí odkaz:
https://doaj.org/article/6701b5761778490aa7e468949244dd8d
Autor:
Wenjun Ni, Jia Ji, Zunyan Dai, Audrey Papp, Amy J Johnson, Sunjoo Ahn, Katherine L Farley, Thomas S Lin, James T Dalton, Xiaobai Li, David Jarjoura, John C Byrd, Wolfgang Sadee, Michael R Grever, Mitch A Phelps
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e13792 (2010)
Flavopiridol is a cyclin-dependent kinase inhibitor in phase II clinical development for treatment of various forms of cancer. When administered with a pharmacokinetically (PK)-directed dosing schedule, flavopiridol exhibited striking activity in pat
Externí odkaz:
https://doaj.org/article/d855ac1e3ffb492e8c542945d869e74a
Autor:
David M Lucas, Lapo Alinari, Derek A West, Melanie E Davis, Ryan B Edwards, Amy J Johnson, Kristie A Blum, Craig C Hofmeister, Michael A Freitas, Mark R Parthun, Dasheng Wang, Amy Lehman, Xiaoli Zhang, David Jarjoura, Samuel K Kulp, Carlo M Croce, Michael R Grever, Ching-Shih Chen, Robert A Baiocchi, John C Byrd
Publikováno v:
PLoS ONE, Vol 5, Iss 6, p e10941 (2010)
While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable
Externí odkaz:
https://doaj.org/article/b8f82372d6bd484e99c19bd6510c448b
Autor:
Anne-Sophie Rebstock, Mareike Wiedmann, Beatrix Stelte-Ludwig, Harvey Wong, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy, Hans-Georg Lerchen
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: The development of bioconjugates for the targeted delivery of anticancer agents is gaining momentum after recent success of antibody drug conjugates (ADCs) in the clinic. Smaller format conjugates may have several advantages including b
Externí odkaz:
https://doaj.org/article/48196de27ca84870b273d09b3f4c3f6d
Autor:
Sara Elgamal, Emanuele Cocucci, Ellen J. Sass, Xiaokui M. Mo, Angela R. Blissett, Edward P. Calomeni, Kerry A. Rogers, Jennifer A. Woyach, Seema A. Bhat, Natarajan Muthusamy, Amy J. Johnson, Karilyn T. Larkin, John C. Byrd
Publikováno v:
JCI Insight, Vol 6, Iss 15 (2021)
In chronic lymphocytic leukemia (CLL) and very likely all cancer types, extracellular vesicles (EVs) are a common mechanism by which intercellular messages are communicated between normal, diseased, and transformed cells. Studies of EVs in CLL and ot
Externí odkaz:
https://doaj.org/article/830710c6a2f04339a049c9c1b33e7304
Autor:
Steven Sher, Ethan Whipp, Janek Walker, Pu Zhang, Larry Beaver, Katie Williams, Shelley Orwick, Janani Ravikrishnan, Brandi Walker, Elizabeth Perry, Charles Gregory, Matthew Purcell, Alexander Pan, Pearlly Yan, Lapo Alinari, Amy J. Johnson, Melanie M. Frigault, Joy M. Greer, Ahmed Hamdy, Raquel Izumi, Xiaokui Mo, Deepa Sampath, Jennifer Woyach, James Blachly, John C. Byrd, Rosa Lapalombella
Publikováno v:
Leukemia. 37:326-338
Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor
Autor:
Cecelia R. Miller, Amy S. Ruppert, Nyla A. Heerema, Kami J. Maddocks, Jadwiga Labanowska, Heather Breidenbach, Gerard Lozanski, Weiqiang Zhao, Amber L. Gordon, Jeffrey A. Jones, Joseph M. Flynn, Samantha M. Jaglowski, Leslie A. Andritsos, Kristie A. Blum, Farrukh T. Awan, Kerry A. Rogers, Michael R. Grever, Amy J. Johnson, Lynne V. Abruzzo, Erin K. Hertlein, James S. Blachly, Jennifer A. Woyach, John C. Byrd
Publikováno v:
Blood Advances, Vol 1, Iss 19, Pp 1584-1588 (2017)
Abstract: Ibrutinib is a highly effective targeted therapy for chronic lymphocytic leukemia (CLL). However, ibrutinib must be discontinued in a subset of patients due to progressive CLL or transformation to aggressive lymphoma (Richter transformation
Externí odkaz:
https://doaj.org/article/a325e38f8d5245adac540764291770ba
Autor:
Anant A. Agrawal, Michael Seiler, Lindsey T. Brinton, Rose Mantel, Rosa Lapalombella, Jennifer A. Woyach, Amy J. Johnson, Ping Zhu, Markus Warmuth, Lihua Yu, John C. Byrd, Peter G. Smith, James S. Blachly, Silvia Buonamici
Publikováno v:
Blood Advances, Vol 1, Iss 15, Pp 995-1000 (2017)
Externí odkaz:
https://doaj.org/article/b8e285b935314e6fbf1de8e2ffe50316
Autor:
Mazyar Shadman, Anthony R. Mato, Connie Lee Batlevi, Ian W. Flinn, Martin Gutierrez, Marc Uemura, Don A. Stevens, Daniel Morillo, John C. Byrd, Melanie M. Frigault, George Clemens, Xin Huang, Raquel Izumi, Harvey Wong, Renee Breed, Hermes Garban, Amy J. Johnson, Beatrix Stelte-Ludwig, Arushi Mithal, Joseph Birkett, Ahmed Hamdy, Kerry A. Rogers
Publikováno v:
Blood. 140:9454-9456